Saventic Health, a Warsaw-based startup revolutionizing rare disease diagnosis with AI, has raised €1.9 million in bridge funding. The round was led by 4growth VC, in co-investment with Poland’s NCBR Investment Fund and the U.S.-based TNI Fund.
The funds will drive expansion into new markets, including Europe, South America, and Canada, while preparing for a Series A funding round. Saventic’s AI technology has diagnosed over 200 rare disease cases in the past year, shortening the typical diagnostic timeframe of 7-12 years.
“Our algorithms are reshaping diagnostics globally, as evidenced by our work with 11 major pharmaceutical firms and 30 clinics across continents,” said Co-founder and CEO Szymon Piątkowski.
The startup, founded in 2019, operates 50 AI algorithms, with its solutions registered as medical devices across the EU and certified in South America. Upcoming targets include Austria, Sweden, Spain, and Colombia, alongside potential U.S. entry post-Series A.
“We’re creating new standards in healthcare innovation by leveraging AI to solve global problems,” added Artur Kluz, General Partner at TNI Fund.
This funding marks TNI Fund’s first investment and increases 4growth VC’s stake, signaling confidence in Saventic’s global scalability.
